Press Releases

Nov 11, 2018

ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) Injection was associated with fewer deaths from any cause

* Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL
Nov 7, 2018

New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial

* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)
Nov 6, 2018

FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Oct 31, 2018

Sanofi Q3 2018 Performance Confirms Return to Growth
- Photos 4
Oct 30, 2018

FDA grants priority review for Sanofi's dengue vaccine candidate

Show per page

Print
Email page
RSS